Tokyo Tape
Sign in
← GNI Group

Half-year report · Q2

2160.TEDINET S100U8GV
Period2024-01-01 → 2024-06-30
Filed2024-08-14
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 62
MetricValuePeriodScopeSource row
Revenue¥11.7bn2024-01-01 → 2024-06-30Cons.Revenue IFRS
Revenue¥5.8bn2024-04-01 → 2024-06-30dCons.Revenue IFRS
Revenue¥26.0bn2023-01-01 → 2023-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥14.1bn2023-01-01 → 2023-06-30Cons.Revenue IFRS
Revenue¥9.9bn2023-04-01 → 2023-06-30dCons.Revenue IFRS
Operating income¥1.8bn2024-01-01 → 2024-06-30Cons.Operating profit loss IFRS
Operating income−¥522m2024-04-01 → 2024-06-30dCons.Operating profit loss IFRS
Operating income¥5.5bn2023-01-01 → 2023-06-30Cons.Operating profit loss IFRS
Operating income¥5.1bn2023-04-01 → 2023-06-30dCons.Operating profit loss IFRS
Profit before tax¥831m2024-01-01 → 2024-06-30Cons.Profit loss before tax IFRS
Profit before tax−¥996m2024-04-01 → 2024-06-30dCons.Profit loss before tax IFRS
Profit before tax¥12.6bn2023-01-01 → 2023-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥5.1bn2023-01-01 → 2023-06-30Cons.Profit loss before tax IFRS
Profit before tax¥5.2bn2023-04-01 → 2023-06-30dCons.Profit loss before tax IFRS
Net income (owners)¥330m2024-01-01 → 2024-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)−¥1.1bn2024-04-01 → 2024-06-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥8.1bn2023-01-01 → 2023-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥1.7bn2023-01-01 → 2023-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥1.7bn2023-04-01 → 2023-06-30dCons.Profit loss attributable to owners of parent IFRS
Net income−¥74m2024-01-01 → 2024-06-30Cons.Profit loss IFRS
Net income−¥1.4bn2024-04-01 → 2024-06-30dCons.Profit loss IFRS
Net income¥9.5bn2023-01-01 → 2023-12-31Cons.Profit loss IFRS (5-year summary)
Net income¥4.0bn2023-01-01 → 2023-06-30Cons.Profit loss IFRS
Net income¥4.4bn2023-04-01 → 2023-06-30dCons.Profit loss IFRS
Total assets¥69.0bnat 2024-06-30Cons.Assets IFRS
Total assets¥62.4bnat 2023-12-31Cons.Assets IFRS
Total assets¥45.1bnat 2023-06-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥29.4bnat 2024-06-30Cons.Liabilities IFRS
Total liabilities¥26.3bnat 2023-12-31Cons.Liabilities IFRS
Net assets / equity¥39.6bnat 2024-06-30Cons.Equity IFRS
Net assets / equity¥36.1bnat 2023-12-31Cons.Equity IFRS
Net assets / equity¥24.8bnat 2023-06-30Cons.Equity IFRS
Net assets / equity¥19.8bnat 2022-12-31dCons.Equity IFRS
Equity (owners)¥36.8bnat 2024-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥33.8bnat 2023-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥23.0bnat 2023-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥16.3bnat 2024-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥21.6bnat 2023-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥14.1bnat 2023-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥11.0bnat 2022-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow−¥1.5bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥6.5bn2023-01-01 → 2023-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥872m2023-01-01 → 2023-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥5.5bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥6.8bn2023-01-01 → 2023-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥2.6bn2023-01-01 → 2023-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥186m2024-01-01 → 2024-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥10.7bn2023-01-01 → 2023-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥3.9bn2023-01-01 → 2023-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥6.612024-01-01 → 2024-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥-22.492024-04-01 → 2024-06-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥169.52023-01-01 → 2023-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥34.932023-01-01 → 2023-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥34.992023-04-01 → 2023-06-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥6.372024-01-01 → 2024-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥-22.492024-04-01 → 2024-06-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥165.562023-01-01 → 2023-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥34.812023-01-01 → 2023-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥34.882023-04-01 → 2023-06-30dCons.Diluted earnings loss per share IFRS
Equity ratio53.4%at 2024-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio54.2%at 2023-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio51.0%at 2023-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 22
SegmentItemPeriodValue
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentrevenue2024-01-01 → 2024-06-30¥2.6bn
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentrevenue external2024-01-01 → 2024-06-30¥2.6bn
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentsegment profit2024-01-01 → 2024-06-30¥676m
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentrevenue2024-01-01 → 2024-06-30¥9.1bn
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentrevenue external2024-01-01 → 2024-06-30¥9.1bn
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentsegment profit2024-01-01 → 2024-06-30¥1.1bn
—segment totalrevenue2024-01-01 → 2024-06-30¥11.7bn
—segment totalrevenue external2024-01-01 → 2024-06-30¥11.7bn
—segment totalsegment profit2024-01-01 → 2024-06-30¥1.8bn
Reconciling Itemsreconcilingrevenue2023-01-01 → 2023-06-30−¥23m
Reconciling Itemsreconcilingrevenue intersegment2023-01-01 → 2023-06-30−¥23m
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentrevenue2023-01-01 → 2023-06-30¥1.4bn
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentrevenue external2023-01-01 → 2023-06-30¥1.3bn
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentrevenue intersegment2023-01-01 → 2023-06-30¥23m
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentsegment profit2023-01-01 → 2023-06-30¥512m
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentrevenue2023-01-01 → 2023-06-30¥12.8bn
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentrevenue external2023-01-01 → 2023-06-30¥12.8bn
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentsegment profit2023-01-01 → 2023-06-30¥5.0bn
—segment totalrevenue2023-01-01 → 2023-06-30¥14.1bn
—segment totalrevenue external2023-01-01 → 2023-06-30¥14.1bn
—segment totalrevenue intersegment2023-01-01 → 2023-06-30¥23m
—segment totalsegment profit2023-01-01 → 2023-06-30¥5.5bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 740
ItemContextValueUnit
Increase of leasehold and guarantee deposits inv cf IFRSCurrentYTDDuration-2714945000JPY
Collection of loans receivable inv cf IFRSPrior1YTDDuration2371000JPY
Collection of loans receivable inv cf IFRSCurrentYTDDuration－JPY
Net cash provided by used in investing activities IFRSPrior1YTDDuration-2585288000JPY
Net cash provided by used in investing activities IFRSCurrentYTDDuration-5522132000JPY
Net increase decrease in short term borrowings fin cf IFRSPrior1YTDDuration800000000JPY
Net increase decrease in short term borrowings fin cf IFRSCurrentYTDDuration2368000000JPY
Repayments of long term borrowings fin cf IFRSPrior1YTDDuration－JPY
Repayments of long term borrowings fin cf IFRSCurrentYTDDuration-200000000JPY
Proceeds from issuance of share acquisition rights fin cf IFRSPrior1YTDDuration－JPY
Proceeds from issuance of share acquisition rights fin cf IFRSCurrentYTDDuration326000JPY
Capital contribution from non controlling interests fin cf IFRSPrior1YTDDuration3239999000JPY
Capital contribution from non controlling interests fin cf IFRSCurrentYTDDuration628389000JPY
Payments for acquisition of interests in subsidiaries from non controlling interests fin cf IFRSPrior1YTDDuration－JPY
Payments for acquisition of interests in subsidiaries from non controlling interests fin cf IFRSCurrentYTDDuration-3269100000JPY
Proceeds from exercise of share acquisition rights fin cf IFRSPrior1YTDDuration－JPY
Proceeds from exercise of share acquisition rights fin cf IFRSCurrentYTDDuration474660000JPY
Repayments of lease obligations fin cf IFRSPrior1YTDDuration-97079000JPY
Repayments of lease obligations fin cf IFRSCurrentYTDDuration-187874000JPY
Payments for purchase of treasury shares fin cf IFRSPrior1YTDDuration-38000JPY
Payments for purchase of treasury shares fin cf IFRSCurrentYTDDuration－JPY
Net cash provided by used in financing activities IFRSPrior1YTDDuration3942881000JPY
Net cash provided by used in financing activities IFRSCurrentYTDDuration-185598000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSPrior1YTDDuration797472000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSCurrentYTDDuration1848584000JPY
Net increase decrease in cash and cash equivalents IFRSPrior1YTDDuration3027443000JPY
Net increase decrease in cash and cash equivalents IFRSCurrentYTDDuration-5326819000JPY
Cash and cash equivalents IFRSPrior2YearInstant11049310000JPY
Cash and cash equivalents IFRSPrior1YearInstant21633028000JPY
Cash and cash equivalents IFRSPrior1QuarterInstant14076753000JPY
Cash and cash equivalents IFRSCurrentQuarterInstant16306208000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q2r_E05712-000PharmaceuticalReportableSegmentMember12768126000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q2r_E05712-000MedicalDeviceReportableSegmentMember1328418000JPY
Revenue from external customers IFRSPrior1YTDDuration_ReportableSegmentsMember14096545000JPY
Revenue from external customers IFRSPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenue from external customers IFRSPrior1YTDDuration14096545000JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E05712-000PharmaceuticalReportableSegmentMember－JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E05712-000MedicalDeviceReportableSegmentMember23197000JPY
Intersegment revenue IFRSPrior1YTDDuration_ReportableSegmentsMember23197000JPY
Intersegment revenue IFRSPrior1YTDDuration_ReconcilingItemsMember-23197000JPY
Intersegment revenue IFRSPrior1YTDDuration－JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E05712-000PharmaceuticalReportableSegmentMember12768126000JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E05712-000MedicalDeviceReportableSegmentMember1351615000JPY
Revenue IFRSPrior1YTDDuration_ReportableSegmentsMember14119742000JPY
Revenue IFRSPrior1YTDDuration_ReconcilingItemsMember-23197000JPY
Revenue IFRSPrior1YTDDuration14096545000JPY
Operating profit loss IFRSPrior1YTDDuration_jpcrp040300-q2r_E05712-000PharmaceuticalReportableSegmentMember4964402000JPY
Operating profit loss IFRSPrior1YTDDuration_jpcrp040300-q2r_E05712-000MedicalDeviceReportableSegmentMember512073000JPY
Operating profit loss IFRSPrior1YTDDuration_ReportableSegmentsMember5476475000JPY
Operating profit loss IFRSPrior1YTDDuration_ReconcilingItemsMember－JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-12-31pass
balance sheet identityconsolidated 2024-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2024-01-01/2024-06-30pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-06-30pass
statement vs summary · operating cash flowconsolidated 2024-01-01/2024-06-30pass
statement vs summary · revenueconsolidated 2023-01-01/2023-06-30pass
statement vs summary · revenueconsolidated 2024-01-01/2024-06-30pass
statement vs summary · total assetsconsolidated 2023-12-31pass
statement vs summary · total assetsconsolidated 2024-06-30pass